- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Tatva Chintan Pharma Chem reported strong Q3 FY26 financial results. Revenue from operations soared to 131.3 Cr, a 53% increase year-on-year. Profit after tax (PAT) saw a significant jump to 15.2 Cr, marking a remarkable 10,889% YoY growth, with Earnings Per Share (EPS) at ₹6.49. For the nine months ending December 2025, revenue reached 371.7 Cr (up 35% YoY) and PAT was 31.7 Cr (up 578% YoY). Operational revenue in Q3 was primarily driven by Structure Directing Agents (41%) and Pharma & Agrochemical Intermediates (36%).
A core strategy involves focusing on 'green' chemistry processes like electrolysis and continuous flow chemistry for sustainable solutions, reduced waste, and improved margins. The company benefits from a diversified product portfolio in niche specialty chemicals, ongoing R&D, and high entry barriers in its segments.
The company is well-positioned to capitalize on India's expanding role in the global chemical market, driven by the 'China+1' policy and the industry's pivot towards sustainable products. The global specialty chemicals market is projected to grow at a 7% CAGR, presenting significant future opportunities, supported by ongoing capital expenditure to boost capacities.